ADORA2A and Alzheimer disease: Our results show that further to the blockade of classical signaling mediated Gs-coupled GPCRs, A2AR antagonists have the potential to combat AD by impacting one of the most relevant pathophysiological molecular mechanisms, namely modulation of NMDAR function.